Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds

Table of Contents

July 1, 2019; Volume 60,Issue 7

Cover image

Cover image expansion

FEATURED ARTICLE

Immuno-PET Imaging to Assess Target Engagement: Experience from 89Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors. C. Willemien Menke-van der Houven van Oordt et al. See page 902.

PET and P2X7 receptors: can a new PET probe reliably differentiate lung inflammation from tumor? Zhequan Fu et al. See page 930.

Novel PSMA-targeting agent: first-in-humans results on 18F-CTT1057 as an alternative to urea-based PET compounds in prostate cancer. Spencer Behr et al. See page 910.

Back to top
PreviousNext

In this issue

Journal of Nuclear Medicine: 60 (7)
Journal of Nuclear Medicine
Vol. 60, Issue 7
July 1, 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author

Issue highlights

  • Immuno-PET Imaging to Assess Target Engagement: Experience from 89Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors
  • P2X7 PET Radioligand 18F-PTTP for Differentiation of Lung Tumor from Inflammation
  • Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer
  • Evaluating the Role of Theranostics in Grade 3 Neuroendocrine Neoplasms
Sign up for alerts

Jump to

  • This Month in JNM
  • Discussions with Leaders
  • Hot Topics
  • The State of the Art
  • Continuing Education
  • Oncology
    • Clinical
      • INVITED PERSPECTIVE
      • FEATURED ARTICLE OF THE MONTH
    • Translational
      • FEATURED TRANSLATIONAL SCIENCE ARTICLE
    • Basic
      • FEATURED BASIC SCIENCE ARTICLE
  • Theranostics
    • Clinical
      • SPECIAL CONTRIBUTION
  • Neurology
    • Clinical
    • Translational
    • Basic
  • Infectious Disease
    • Clinical
  • Radiochemistry
    • Basic
  • Instrumentation
  • Erratum
  • SNMMI Newsline
  • Most Cited
  • Most Read
Loading
  • Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer
  • First-in-Human Assessment of 11C-LSN3172176, an M1 Muscarinic Acetylcholine Receptor PET Radiotracer
  • Impact of 68Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study
  • Tau PET imaging with 18F-PI-2620 in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans Study
  • Radiation Dosimetry in 177Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors
More...
SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire